Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

FDA reinspection, apitegromab BLA resubmission and 2026 launch outlook, plus cash and new debt facility—read now.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...

Now looking beyond NASH, PEMB has the potential to address major unmet medical needs in both AUD and ALD because of a similar ...

Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the best hot stocks under $20 to buy. Wave Life Sciences Ltd. (NASDAQ:WVE) released its fiscal Q4 and full-year 2025 earnings on February 26, reporting ...

The best savings accounts, CDs, and other low-risk options still pay 3%–5% on idle cash Sabrina Karl has over two decades of experience writing about savings, CDs, and other banking topics. She is ...

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and ...

WAVE Life Sciences (NASDAQ:WVE) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight ...

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsCompany expects to complete enrollment of ...

Secretary of Education Linda McMahon called Alpha School's AI-only teaching the future. Credit: Rick Kern / Getty Images for Alpha School Could you learn all that you need to know about reading, ...

PureWow editors select every item that appears on this page, and some items may be gifted to us. Additionally, PureWow may ...

Q4 2025 Management View CEO Douglas Ingram stated that Sarepta entered 2026 on "a strong footing" with three pillars: financial strength, durable therapies, and a robust pipeline. "We exited 2025 with ...